Other Cancers

11 protocols meet the specified criteria.

• A151804

  Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

• A211901

  Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

• COG-AGCT1531

  A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

• EAY191

  Molecular Analysis for Combination Therapy Choice (ComboMATCH)

• GRAIL-MA-001

  REFLECTION: Real World Evidence for Learnings in Early Cancer Detection, a Clinical Practice Learning Program for Galleri

• GRAIL-MA-002

  REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

• NRG-CC014

  Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)

• S2012

  Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

• WVU020924

  Phase I/II study of leflunomide in combination with decitabine for treatment of relapsed or refractory myelodysplastic syndromes

• WVU03HSC24

  Evaluating the gut microbiome from diagnosis through surveillance in colorectal cancer patients in Appalachia

• XPORT-MF-034

  A Phase 1 / Phase 3 Study to Evaluate the Efficacy and Safety of Selinexor, A Selective Inhibitor of Nuclear Export, in Combination with Ruxolitinib in Treatment-Naïve Patients with Myelofibrosis